Trademarkia Logo

Canada

C$
Trademark Search in Canada
CONTERA PHARMA & DESIGN

View On IC.GC.CA

CONTERA PHARMA & DESIGN
REGISTERED

on 19 Aug 2019

Last Applicant/ Owned by

CONTERA PHARMA APS

Ole Maaløes Vej 32200 København N

DK

Serial Number

1747244 filed on 10th Sept 2015

Registration Number

TMA1049894 registered on 19th Aug 2019

Registration expiry Date

19th Aug 2029

Correspondent Address

DEETH WILLIAMS WALL LLP

150 YORK STREET, SUITE 400TORONTO

ONTARIO

CA

M5H3S5

CONTERA PHARMA & DESIGN

Trademark usage description

antibiotics; antivirals, chemical preparations for pharmaceutical purposes, namely, for the treatment, prevention or alleviation of diseases of the ce Read More

Vienna Information

26 . 11 . 1

One line or one bandUne ligne ou une bande

26 . 11 . 8

Horizontal lines or bandsLignes ou bandes horizontales

26 . 11 . 11

Broken lines or bands (except a 26.11.13)Lignes ou bandes brisées (excepté a 26.11.13)

29 . 1 . 4

BlueBleu

Classification Information

Class [005]
Antibiotics; antivirals, chemical preparations for pharmaceutical purposes, namely, for the treatment, prevention or alleviation of diseases of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, central nervous system infections, brain diseases, central nervous system movement disorders, ocular mobility disorders, and spinal cord diseases, neurological disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, psychiatric disorders, namely, schizophrenia, mood disorders, anxiety disorders, and cognitive disorders, extrapyramidal disorders, hyperkinetic movement disorders, hypokinetic movement disorders, parkinsonism, Parkinson's Disease, dyskinesias and complications arising from same; drugs for medical purposes, namely, pharmaceutical preparations for the treatment, prevention or alleviation of diseases of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, central nervous system infections, brain diseases, central nervous system movement disorders, ocular mobility disorders, and spinal cord diseases, neurological disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, psychiatric disorders, namely, schizophrenia, mood disorders, anxiety disorders, and cognitive disorders, extrapyramidal disorders, hyperkinetic movement disorders, hypokinetic movement disorders, parkinsonism, Parkinson's Disease, dyskinesias and complications arising from same; medicines for human purposes for the treatment, prevention or alleviation of diseases of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, central nervous system infections, brain diseases, central nervous system movement disorders, ocular mobility disorders, and spinal cord diseases, neurological disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, psychiatric disorders, namely, schizophrenia, mood disorders, anxiety disorders, and cognitive disorders, extrapyramidal disorders, hyperkinetic movement disorders, hypokinetic movement disorders, parkinsonism, Parkinson's Disease, dyskinesias and complications arising from same; pharmaceutical preparations for the treatment, prevention or alleviation of diseases of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, central nervous system infections, brain diseases, central nervous system movement disorders, ocular mobility disorders, and spinal cord diseases, neurological disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, psychiatric disorders, namely, schizophrenia, mood disorders, anxiety disorders, and cognitive disorders, extrapyramidal disorders, hyperkinetic movement disorders, hypokinetic movement disorders, parkinsonism, Parkinson's Disease, dyskinesias and complications arising from same; vitamin preparations; health supplements for medical use, namely, health food supplements, dietary and nutritional supplements, and herbal supplements, all for general health and well-being, and for the treatment, prevention or alleviation of diseases of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, central nervous system infections, brain diseases, central nervous system movement disorders, ocular mobility disorders, and spinal cord diseases, neurological disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, psychiatric disorders, namely, schizophrenia, mood disorders, anxiety disorders, and cognitive disorders, extrapyramidal disorders, hyperkinetic movement disorders, hypokinetic movement disorders, parkinsonism, Parkinson's Disease, dyskinesias and complications arising from same.

Classification kind code

11

Class [035]
Business information on pharmaceuticals; business management assistance on pharmaceuticals; market research services; conducting marketing studies; arranging of pharmaceutical sale.

Classification kind code

11

Mark Details

Serial Number

1747244

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 50
on 15th Sept 2017		Allowed
Submitted for opposition 42
on 31st May 2017		Advertised
Submitted for opposition 26
on 11th May 2017		Approved
Submitted for opposition 130
on 11th Apr 2017		Note to file
Submitted for opposition 27
on 22nd Mar 2017		Approval Notice Sent
Submitted for opposition 22
on 31st May 2016		Search Recorded
Submitted for opposition 20
on 31st May 2016		Examiner's First Report
Submitted for opposition 1
on 23rd Sept 2015		Created
Submitted for opposition 31
on 23rd Sept 2015		Formalized
Submitted for opposition 30
on 10th Sept 2015		Filed